Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2015—The Methotrexate ELISA kit from Enzo Life Sciences enables the monitoring of methotrexate levels during treatment of cancer and rheumatoid arthritis. The assay is also appropriate for the detection of methotrexate contamination after its use as a selective agent for recombinant protein production in mammalian cell lines.
May 2015—Sarstedt is offering two urine collection systems—the Urine Monovette and the V-Monovette. The Urine Monovette enables hygienic urine collection and testing without needles, adapters, or cups or transfers. All tubes are manufactured from impact-resistance, medical-grade plastics and feature secure screw caps for safe handling. After collection using a syringe technique, the plunger handle is removed to create a primary tube for transport, direct analysis, and centrifugation. A Luer-lock version is also available for needleless collection from Foley catheters.
May 2015—Bio-Rad announced the launch of the BioPlex 2200 25-OH Vitamin D kit for use on the company’s BioPlex 2200 system in U.S. markets. The assay offers a fully automated method for the quantitative measurement of total 25-hydroxyvitamin D in human serum.
May 2015—Radiometer has announced the launch of a dedicated Individualized Quality Control Plan tool for hospitals using the ABL90 Flex blood gas analyzer. The IQCP tool provides a template for hospitals with ABL90 Flex analyzers to develop a customized quality control plan. Starting at the preanalytical phase, the tool next guides the laboratorian through the analytical and postanalytical processes, identifying key areas of focus to ensure the development of an IQCP program that is right for each institution.
May 2015—The Digital Pathology Association is commending the FDA for developing and releasing draft guidance that provides industry and agency staff with recommendations regarding the technical performance assessment data that should be submitted for regulatory evaluation of a digital whole-slide imaging system.
April 2015—Agena Bioscience released the MassArray 24-Well System for mass spectrometry-based genetic analysis. The 24-well format is tailored to smaller clinical testing laboratories requiring modest sample throughput, reduced initial hardware costs, and reduced time to result.
April 2015—Qiagen has expanded its portfolio of liquid biopsies through the acquisition of a proprietary technology from AdnaGen. The technology allows a complete solution for the detection and analysis of circulating tumor cells for clinical applications. It enriches disease-specific tumor cells using magnetic particles in an antibody mixture, then isolates and purifies messenger RNA for analysis using reverse transcription polymerase chain reaction.
April 2015—Eppendorf and the journal Science are accepting applications for the 2015 Eppendorf & Science Prize for Neurobiology.
April 2015—The diagnostics division of Siemens Healthcare has announced the U.S. availability of its Advia Centaur Syphilis assay to be used as a diagnostic aid. The assay, which allows for sensitive and specific detection of antibodies to the proteins of Treponema pallidum in human serum or plasma (EDTA, lithium or sodium heparinized, sodium citrate), is available on the company’s Advia Centaur, Centaur XP, and Centaur CP immunoassay systems. It is not intended for blood and tissue donor screening.
April 2015—Rosetta Genomics has entered into a co-promotional commercial partnership with Precipio Diagnostics for the sales and marketing of Precipio’s oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas. These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia, and Washington, DC, with an expectation to expand nationally over time.
